Last updated: February 24, 2026
What is NDC 60505-0827?
NDC 60505-0827 corresponds to a specific marketed drug, identified through the National Drug Code (NDC) system. Data shows this NDC refers to Sodium Hyaluronate injection used primarily for osteoarthritis pain management via intra-articular injection.
Market Landscape
Indication and Usage
Sodium Hyaluronate injections target osteoarthritis of the knee, shoulder, and other joints. The global osteoarthritis treatment market was valued at approximately $8.1 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 4.9% through 2030[^1].
Competition
Primary competitors include:
| Brand Name |
Manufacturer |
Strength |
Formulation |
| Euflexxa |
Ferring Pharmaceuticals |
20 mg/2 mL |
Sterile, preservative-free viscous solution |
| Synvisc-One |
Genzyme (a Sanofi company) |
16 mg/3 mL |
Cross-linked hyaluronan |
| Gelsyn-3 |
Anika Therapeutics |
20 mg/2 mL |
Hyaluronan injection |
| Orthovisc |
Anika Therapeutics |
20 mg/2 mL |
Viscosupplement |
Market share
Euflexxa remains a leading product due to approved indications for knee osteoarthritis with a broad clinician base. Gelsyn-3 entered the market post-2020, gaining market share through competitive pricing and formulary placements.
Pricing Dynamics
Wholesale acquisition cost (WAC) for sodium hyaluronate products ranged from approximately $300 to $600 per 2-mL dose (2023). Reimbursement rates vary based on payer and geographic region, impacting pharmacy and patient costs.
Regulatory Status and Approvals
Current FDA Status
- Original approval: 2010 for osteoarthritis knee pain (specific products vary)
- Marketed as a prescription viscous supplement under FDA guidelines
- No recent changes to approval status or new indications for NDC 60505-0827
Off-label Use and Emerging Indications
Off-label applications include use in tendon and ligament repair. Preliminary studies suggest potential for broader orthopedic applications, which could influence future demand.
Price Projections (2023-2030)
Factors Influencing Prices
- Increased adoption driven by aging populations and osteoarthritis prevalence.
- Patent expirations or market entries by biosimilars or generics could pressure prices.
- Reimbursement policies and healthcare reforms aim to reduce costs for payers and patients.
Short-term (2023-2025)
- Prices are expected to remain stable as market incumbents compete through formulary negotiations.
- Average WAC for the product likely remains in the $400-$600 range per dose.
- Reimbursement rates may influence net prices slightly lower.
Medium-term (2026-2030)
- Entry of biosimilars or competing formulations may induce price cuts of 10-20% per year.
- As provider familiarity increases, volume growth could stabilize or increase prices slightly due to demand.
Long-term (post-2030)
- Market saturation and payer pressures may compress prices further.
- Price points could decline towards $250-$350 per dose with widespread biosimilar competition.
- Innovation in delivery or indications might support premium pricing temporarily.
Revenue Forecasts
Assuming the following parameters:
- 1 million annual treatment doses nationally (U.S.)
- Average price: $500 per dose (2023)
- Market penetration increases to 80% over five years
Estimated revenue 2023: $500 million
Projected revenue 2030: $1.2 billion, assuming growth in demand and dosage volume.
Key Market Risks
- Patent expirations and generic entry.
- Changes in reimbursement policies reducing payor reimbursement.
- Development of alternative therapies, such as platelet-rich plasma (PRP) and regenerative medicine, decreasing demand.
Key Takeaways
- NDC 60505-0827 corresponds to sodium hyaluronate injections used for osteoarthritis.
- The market features established competitors with pricing typically between $300-$600 per dose.
- Price projections suggest stability short-term, with potential declines due to biosimilar competition by 2026-2030.
- Demand growth driven by aging populations may sustain revenue growth despite price pressures.
- Market risks include patent expirations and emerging alternative therapies.
FAQs
Q1: What factors could cause prices for NDC 60505-0827 to decrease significantly?
Entry of biosimilars, reduced reimbursement rates, and increased generic competition are primary factors.
Q2: How does the current market share impact future pricing?
Established market leaders maintain higher prices; new entrants or increased competition may drive prices down.
Q3: Are there regulatory hurdles affecting price projections?
No major regulatory changes are expected; however, policy shifts toward cost containment could impact reimbursement.
Q4: What is the forecasted demand growth for osteoarthritis treatments?
Demand is projected to grow at approximately 4.9% CAGR through 2030, driven by aging populations.
Q5: How might technological innovation influence prices?
Development of regenerative therapies and alternative delivery methods could render current products less competitive, affecting prices.
References
[1] MarketWatch. (2023). Global osteoarthritis treatment market size, share, growth 2022-2030.
[2] IQVIA. (2023). Osteoarthritis market data and insights.
[3] U.S. Food and Drug Administration. (2022). Approved products and labels for sodium hyaluronate.
